Eli Lilly and Company: Lilly reports full Q4 2024 financial results and provides 2025 guidance Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound.

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Lone Pine Capital’s Q1 2025 13F portfolio value dropped to $11.58B, with holdings reduced from 30 to 22, focusing on top tech ...

While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...